Featured Oncology News
Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.
The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.
AbbVie Announces Results from Phase 2 Study Evaluating Rovalpituzumab Tesirine (Rova-T) for Third-Line Treatment of Patients with DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer
Phase III IMpower150 Study Showed Roche’s TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Plus Carboplatin And Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared To Avastin Plus Carboplatin And Paclitaxel
Two Studies Provide a Framework for a New Quality Improvement Program for Rectal Cancer, Showing the Value of a Multidisciplinary Team Approach
Pipeline Online is the most comprehensive and up to date oncology pipeline information resource that is widely available on the web ...
OBR Finance tracks the market performance of oncology companies and products, and compares our performance versus other indices ...
OBR Radar is a snapshot of upcoming pivotal events in the oncology industry such as FDA action dates, anticipated announcement of pivotal clinical data, and ODAC dates ...
Charleston, WV
Chicago, IL
Baton Rouge, LA
Spokane, WA
Amsterdam, The Netherlands
New York, NY
Phoenix, AZ
Phoenix, AZ
Phoenix, AZ
Washington, DC
Featured Content
Previous
News Story Commentary
Meet the Editorial BoardView all Commentary
U.S. Food and Drug Administration Accepts Supplement...
April 19th 2018 by H. Jack West, MD
This will be a welcome addition to our very limited armamentarium for small cell lung cancer. This ...
Read More
US FDA Approves Tagrisso As 1st-Line Treatment For E...
April 19th 2018 by H. Jack West, MD
A long overdue approval that most lung cancer specialists should have come shortly after presentati...
Read More
Patients with Advanced Lung Adenocarcinoma and Compl...
April 13th 2018 by H. Jack West, MD
This is a very interesting contribution. We know the response rate to first line EGFR TKIs is 70-80...
Read More
Payment Bundles That Include Drug Costs May Destabil...
April 13th 2018 by Dean Gesme, MD
There is no quicker way to "burn out" physicians than to put them "at risk" for expenses that they ...
Read More
Cancer Risk Rises as Patients Wait for Diagnostic Te...
April 11th 2018 by Thomas Marsland, MD
This article really hit home with me. As I have transitioned through my career I've had to...
Read More
KEYTRUDA® (pembrolizumab) Monotherapy Met Primary E...
April 09th 2018 by H. Jack West, MD
**Practice-changing result**! We obviously need to see the data, but this large phase 3 trial n...
Read More
OBR Green